Advanced search
Publication Cover
Journal of Drug Targeting Volume 4, 1996 - Issue 2
Submit an article Journal homepage
36
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Alternate drug delivery routes for A-71623, a potent cholecystokinin-a receptor agonist tetrapeptide

John Cannon Abbott Laboratories, D-493, 100 Abbott Park Road AP-9
,
L. Adjei Abbott Laboratories, D-493, 100 Abbott Park Road AP-9
,
Mou-Ying Lu Abbott Laboratories, D-493, 100 Abbott Park Road AP-9
&
Kevin Garren Abbott Laboratories, D-493, 100 Abbott Park Road AP-9
Pages 69-78 | Received 08 Sep 1995, Accepted 26 Feb 1996, Published online: 20 Oct 2008

References

  • A. Inui, M. Okita, T. Inoue, N. Sakatani, M. Oya, H. Moriaka, M. Oinomi, S. Baba.(1989). “Effect of Cholecystokinin octapeptide analogs on food intake in the dog.” Am. J. Physiol. 257:R946–R951.
  • J. Gibbs, J. Falasco, P. McHugh.(1976). “Cholecystokinin decreased food intake in rhesus monkeys.” Am. J. Physiol. 230:15–18.
  • J. Gibbs, R. Young, G. Smith.(1973). “Cholecystokinin decreases food intake in rats.” J. Comp. Physiol. Psychol. 84:488–495.
  • H. Kissileff, F. Pi‐Sunyer, J. Thornton, J. Smith.(1981). “C‐terminal octapeptide of Cholecystokinin decreases food intake in man.” Am. J. Clin. Nutr. 34:154–160.
  • C. Lin, K. Shiosaki, T. Miller, D. White, B. Bianchi, C. Wolfram, H. Kopecka, R. Craig, F. Wagenaar, A. Nadzan.(1991). “Characterization of two novel Cholecystokinin tetrapeptide (30–33) analogues, A‐71623 and A‐70874, that exhibit high potency and selectivity for Cholecystokinin‐A receptors,” Mol. Pharmacol. 39:346–351.
  • K. Asin, L. Bednarzz, A. Nikkei, P. Gore, W. Montana, M. Cullen, K. Shiosaki, R. Craig, A. Nadzan.(1992a). “Behavioral effects of A‐71623, a highly selective CCK‐A agonist tetrapeptide,” Am. J. Physiol. 263:R125–R135.
  • K. Asin, L. Bednarz, A. Nikkel, P. Gore, A. Nadzan.(1992b). “A‐71623, a selective CCK‐A receptor agonist, suppresses food intake in the mouse, dog and monkey,” Pharmacol. Biochem. Behav. 42:699–704.
  • R. Elliot, K. Kopecka, M. Bennett, Y. Shue, R. Craig, C. Lin, B. Bianchi, T. Miller, D. Witte, M. Stashko, K. Asin, A. Nikkei, L. Bednarz, A. Nadzan.(1994). “Tetrapeptide CCK agonists: Structure‐activity studies on modifications at the N‐terminus” J. Med. Chem. 37:309–313.
  • A. Adjei, J. Garren.(1990). “Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy human male volunteers” Pharm. Res. 61:135–144.
  • R. Bronaugh, R. Stewart.(1985). “Methods for In Vitro Percutaneous Absorption Studies IV: the Flow‐Through Diffusion Cell” J. Pharm. Sci. 69:64–67.
  • S. Silvestri, M. FuLu, H. Johnson.(1993). “Kinetics and Mechanisms of Peptide aggregation: Aggregation of a cholecystokinin analogue” J. Pharm. Sci. 82:689–693.
  • A. Adjei, R. Doyle, R. Finley, E. Johnson.(1990). “Bioavailability of Leuprolide Following Intratracheal Administration to Beagle Dogs” Int. J. Pharm. 61:135–144.
  • J. Garren, K. Marsh, L. Adjei.(1990). Intratracheal Absorption of a Poorly Orally Absorbed Renin Inhibitor Pharm. Res. 7:S‐134
  • A. Coutel‐Egros, Y. Maitani, M. Veillard, Y. Machida, T. Nagai.(1992). “Combined effects of pH, cosolvent and penetration enhancers on the in vitro buccal absorption of propranolol through excised hamster cheek pouch” Int. J. Pharm. 84:117–128.
  • D. Kobayashi, T. Matsuzawa, K. Sugibayashi, Y. Morimoto, M. Kobayashi, M. Kimura.(1993). “Feasibility Of Use Of Several Cardiovascular Agents In Transdermal Therapeutic Systems With L‐Menthol‐Ethanol System On Hairless Rat And Human Skin” Biol. Pharm. Bull. 16:254–258.
  • M. FuLu, D. Lee, G. Subba Rao.(1992). “Percutaneous absorption enhancement of leuprolide.” Pharm. Res. 9:1575–1579.
  • V. Lee.(1986). Delivery Systems For Peptide Drugs87–104.
  • J. Padfield.(1987). Drug Delivery to The Respiratory Tract
  • V. Anderson.R. McLean.(1974). Design of Experiments: A Realistic Approach342–348.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.